Sutezolid

DRUG4 trials

Sponsors

Global Alliance for TB Drug Development, Michael Hoelscher, The Aurum Institute NPC, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Other Specified Pulmonary TuberculosisPulmonary TuberculosisTuberculosisTuberculosis, Pulmonary

Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid

CompletedNCT03199313

Global Alliance for TB Drug DevelopmentTuberculosis, Tuberculosis, Pulmonary

Start: 2017-09-26End: 2017-12-16Updated: 2018-02-08

Phase 2

PanACEA Sutezolid Dose-finding and Combination Evaluation

CompletedNCT03959566

Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculosis

Start: 2021-05-06End: 2022-09-30Updated: 2023-05-01

A Pan-TB Regimen Targeting Host and Microbe

Active, not recruitingNCT05686356

The Aurum Institute NPCTuberculosis

Start: 2023-07-28End: 2026-01-31Target: 352Updated: 2025-05-28

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

RecruitingNCT06192160

National Institute of Allergy and Infectious Diseases (NIAID)Pulmonary Tuberculosis

Start: 2025-03-11End: 2027-08-11Target: 315Updated: 2026-03-19

Related Papers

panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe

Trials2026-02-27

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis

Trials2025-08-152 citations

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial.

2025-07-085 citations

Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants

Antimicrobial Agents and Chemotherapy2025-03-112 citations

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis.

2023-06-0611 citations